New Haven oncology biotech Cybrexa Therapeutics has agreed to work with the National Cancer Institute (NCI) on developing Cybrexa’s tumor-targeting drug, CBX-12.
Under terms of the agreement, Cybrexa and the NCI will collaborate on pre-clinical and potential clinical development of the drug. NCI is part of the National Institutes of Health.